HomeInsightsStock Comparison

Marksans Pharma Ltd vs Morepen Laboratories Ltd Stock Comparison

Marksans Pharma Ltd vs Morepen Laboratories Ltd Stock Comparison

Last Updated on: Jul 01, 2025

Key Highlights

  • The Latest Trading Price of Marksans Pharma Ltd is ₹ 257.85 as of 01 Jul 14:19.
  • The P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 21.9 on March 2024 . This represents a CAGR of 36.04% over 5 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 12.7 on March 2020 to 22.4 on March 2024 . This represents a CAGR of 12.02% over 5 years.
  • The Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 6867 crore on March 2024 . This represents a CAGR of 64.57% over 5 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 429.13 crore on March 2020 to ₹ 2149 crore on March 2024 . This represents a CAGR of 38.03% over 5 years.
  • The revenue of Marksans Pharma Ltd for the Mar '25 is ₹ 724.98 crore as compare to the Dec '24 revenue of ₹ 709.7 crore. This represent the growth of 2.15% The revenue of Morepen Laboratories Ltd for the Mar '25 is ₹ 470.46 crore as compare to the Dec '24 revenue of ₹ 458.12 crore. This represent the growth of 2.69%.
  • The ebitda of Marksans Pharma Ltd for the Mar '25 is ₹ 142.27 crore as compare to the Dec '24 ebitda of ₹ 166.61 crore. This represent the decline of -14.61% The ebitda of Morepen Laboratories Ltd for the Mar '25 is ₹ 46.85 crore as compare to the Dec '24 ebitda of ₹ 41.48 crore. This represent the growth of 12.95%.
  • The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 90.73 crore over 8 quarters. This represents a CAGR of 13.49% The net profit of Morepen Laboratories Ltd changed from ₹ 14.63 crore to ₹ 20.31 crore over 8 quarters. This represents a CAGR of 17.82% .
  • The Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 20.33 % on March 2024 . This represents a CAGR of 13.49% over 5 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

About Morepen Laboratories Ltd

  • Morepen Laboratories Limited is an India-based pharmaceutical company.
  • Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
  • The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
  • It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
  • The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

Marksans Pharma Ltd News Hub

News

Time-Cap Laboratories successfully concludes USFDA inspection

Marksans Pharma announced that its subsidiary, Time-Cap Laboratories Inc. has received the...

Read more

30 Jun 2025 12:56

News

Marksans Pharma rises after subsidiary gets EIR for New York-based facility from US FDA

In April this year, the United States Food and Drug Administration (US FDA) had conducted ...

Read more

30 Jun 2025 12:58

News

Marksans Pharma's UK arm gets marketing nod for Oxybutynin Oral solution from UKMHRA

Oxybutynin is used in the treatment of overactive bladder (OAB) symptoms. OAB is a collect...

Read more

19 Jun 2025 10:04

News

Relonchem receives marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution in UK

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

30 May 2025 09:13

News

Marksans Pharma gets regulatory nod for marketing type-2 diabetes medication in UK

Metformin Hydrochloride is a widely prescribed medication used for the management of type-...

Read more

30 May 2025 09:33

News

Board of Marksans Pharma recommends final dividend

Marksans Pharma announced that the Board of Directors of the Company at its meeting held o...

Read more

20 May 2025 12:49

Morepen Laboratories Ltd News Hub

News

Morpen Labs incorporates subsidiary in Dubai

The newly formed wholly owned subsidiary namely Morepen Labs ' FZCO, will trade in pharmac...

Read more

19 Jun 2025 08:44

News

Board of Morepen Laboratories approves availing of working capital loan of Rs 50 cr

The Board of Morepen Laboratories at its meeting held on 23 May 2025 has approved inter-al...

Read more

23 May 2025 10:25

News

Board of Morepen Laboratories notes incorporation of step-down subsidiary in Dubai

The Board of Morepen Laboratories at its meeting held on 12 May 2025 has noted the decisio...

Read more

12 May 2025 18:29

News

Board of Morepen Laboratories recommends Final Dividend

Morepen Laboratories announced that the Board of Directors of the Company at its meeting h...

Read more

12 May 2025 16:11

News

Morepen Laboratories to announce Quarterly Result

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 Ma...

Read more

06 May 2025 11:55

News

Morepen receives CDSCO nod to conduct BE studies for Resmetirom

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drug...

Read more

29 Apr 2025 09:07

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Morepen Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Morepen Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Marksans Pharma Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Marksans Pharma Ltd or Morepen Laboratories Ltd?

Market cap of Marksans Pharma Ltd is 11,857 Cr while Market cap of Morepen Laboratories Ltd is 3,385 Cr

What are the key factors driving the stock performance of Marksans Pharma Ltd and Morepen Laboratories Ltd?

The stock performance of Marksans Pharma Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Marksans Pharma Ltd and Morepen Laboratories Ltd?

As of July 1, 2025, the Marksans Pharma Ltd stock price is INR ₹261.65. On the other hand, Morepen Laboratories Ltd stock price is INR ₹61.78.

How do dividend payouts of Marksans Pharma Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Marksans Pharma Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions